Eisai
Joel Krasnow MD MBA is an experienced professional in the pharmaceutical industry, currently serving as Vice President of Clinical Development at Eisai Pharmaceuticals since 2011, overseeing all clinical development projects, including a pediatric program for Aciphex. Prior roles include Executive Director at Eisai, where responsibility encompassed clinical programs in immunology and gastroenterology, and Senior Director at Roche Pharmaceuticals, leading clinical data analysis for Tociluzimab, which achieved global product approvals. Previous positions also include Senior Medical Director at Novartis Pharmaceuticals and Medical Director at Pfizer, with extensive experience in strategic development, clinical program leadership, and healthcare consulting. Joel Krasnow holds an MD from McGill University and an MBA from the University of Pittsburgh Katz Graduate School of Business.
This person is not in any teams
This person is not in any offices
Eisai
12 followers
Eisai Co., Ltd. is engaged in the research and development, manufacture, sale and import and export of pharmaceuticals. The Company's business segments include pharmaceutical segment and other segment. The pharmaceutical segment is engaged in the research, develop, manufacture and sale of pharmaceuticals for medical use, generic drugs, general medicines, among others. The other segment consists of pharmaceutical raw materials, logistics services and business services businesses.